News

  1. Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™ 11/29/2012

    Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.

  2. TiGenix Completes Patient Enrollment In Phase IIa Rheumatoid Arthritis Study 8/8/2012

    TiGenix (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis.

  3. Titan Completes Preclinical Study Of A Continuous, Dopamine Agonist Treatment for Parkinson's Disease 7/10/2012

    Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it has successfully completed investigation into the feasibility of a long-term, round-the-clock, non-fluctuating dopamine agonist treatment for Parkinson's disease. The preclinical study was primarily funded by a $495,000 grant awarded to Titan by the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program, and administered by the National Institute of Neurological Disorders and Stroke (NINDS).

  4. Next Front In Worldwide AIDS Battle: Stretching Use Of Anti-HIV Drugs 7/5/2012

    A Johns Hopkins expert in the drug treatment of HIV disease and AIDS is spearheading an international effort to radically shift the manufacturing and prescribing of combination therapies widely credited in the last decade for keeping the disease in check for 8 million of the 34 million infected people worldwide. 

  5. Oncos Therapeutics Announces Clinical Advisory Board For Its Oncolytic Virus And Cancer Immunotherapy Development Programs 7/5/2012

    Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB).